

## PROJECT CACTUS

### CONFIDENTIALITY AND JOINT DEFENCE AGREEMENT

**THIS CONFIDENTIALITY AND JOINT DEFENCE AGREEMENT (THE "AGREEMENT") IS ENTERED INTO BY AND AMONG THE UNDERSIGNED AS OF 20 NOVEMBER 2021.**

**WHEREAS**, Triton Investment Management Limited ("**Triton**"), in its capacity indirectly or directly as manager of funds known together as Triton V, and Clinigen Group plc (together with its subsidiaries and affiliates, "**Clinigen**") (collectively, the "**Clients**" individually, the "**Client**") are in preliminary discussions regarding a potential transaction involving the acquisition of Clinigen by a newly incorporated company incorporated by funds managed or advised by Triton or its affiliates (the "**Transaction**");

**WHEREAS**, the Clients and their undersigned counsel believe that the Transaction will require them to apply for clearances or approvals to the antitrust and/or regulatory authorities in one or more jurisdictions (the "**Matter**");

**WHEREAS**, the Clients and their undersigned counsel believe and anticipate, on the basis of currently available information, that the nature of the Matter and the relationship among the Clients will present various common legal and factual issues and a mutuality of interest in pursuing the Transaction and any joint defence in connection with the Matter and any related litigation;

**WHEREAS**, the Clients wish to continue to pursue their separate but common interests, and to avoid any suggestion of waiver of the confidentiality or immunity of communications and documents protected by the attorney-client privilege, the attorney work product doctrine or any other privilege, right or immunity vis-à-vis potentially adverse parties;

**WHEREAS**, it is the intention and understanding of the Clients and undersigned counsel that past and future communications relating to the Matter among and between the Clients and their undersigned counsel and experts retained by one or more of the Clients or their undersigned counsel to assist with the Matter, joint interviews of prospective witnesses or any interviews obtained by undersigned counsel on behalf of a Client (in each case relating to the Matter) hereto with the knowledge and consent of the other Clients to the Agreement, are and shall remain confidential and are and shall continue to be protected from disclosure to any third party by any and all applicable privileges, rights and immunities, except as set forth herein;

**WHEREAS**, in order to pursue a joint defence effectively, the Clients and their undersigned counsel have also each concluded that, from time to time, their interests will be best served by sharing confidential documents, factual material, mental impressions, advice, memoranda, interview reports, litigation or regulatory strategies, regulatory filings and other information, whether proceeding from or shared by the Clients or any of their respective subsidiaries, whether in written or oral form, including the confidences of each Client (collectively, the "**Defence Materials**");

**WHEREAS**, Defence Materials that contain commercially sensitive information relating to a Client which that Client considers should be provided on an "Outside Counsel/Retained Experts Only" basis ("**Restricted Information**") may be disclosed to certain external lawyers or economists advising the other Client in order to consider the need for and, where necessary, obtain the consent of a competition authority or other regulatory body;

**WHEREAS**, the Clients have entered into a confidentiality undertaking letter dated 13 November 2021 (the "**NDA**") generally governing the disclosure of confidential information between them in connection with the Transaction and will enter into a clean team protocol agreement to be agreed between the Clients, if required, (the "**Clean Team Protocol**"). The terms of the NDA and Clean Team Protocol (if entered into) shall apply to the Restricted Information subject to the amendments and modifications set out in this Agreement; and

**WHEREAS**, it is the purpose of this Agreement to ensure that any exchange and/or disclosure of the Defence Materials contemplated herein does not diminish in any way the confidentiality of the Defence Materials and does not constitute a waiver of any privilege, right or immunity otherwise available, and further to ensure that any Restricted Information relating to Clinigen provided on an "Outside Counsel/Retained Experts Only" basis need not be provided directly to any competing offeror, but instead provided on the same restricted "Outside Counsel/Retained Experts Only" basis.

1. **IT IS THEREFORE AGREED AS FOLLOWS:**

- 1.1 Except as expressly stated in writing to the contrary (including, in particular, the additional restrictions described below in relation to the treatment of Restricted Information), any and all Defence Materials obtained by any of the undersigned counsel from each other and/or each other's Client are being provided solely for use in relation to the Matter by the Clients, their undersigned counsel and other external advisers and external experts employed in relation to the Matter and shall remain confidential and shall be protected from disclosure to any other third party by the joint-defence privilege, the Client's attorney-client and solicitor-client privilege, the attorney work product doctrine, common interest privilege, legal professional privilege, legal advice privilege, litigation privilege and any and all other applicable privileges and immunities. All Defence Materials shall be used solely in connection with the Matter and shall not be used for any other business or commercial purpose whatsoever. Failure to mark Defence Materials as confidential shall not waive the confidential status of such privileged information or work product.
- 1.2 Restricted Information will be marked with an "Outside Counsel/Retained Experts Only" (or equivalent) legend, heading, or subject line. The undersigned counsel hereby agree that to the extent that Restricted Information is disclosed to them, it will be kept confidential and disclosed only to (i) competition or regulatory partners, associates, employees or other staff (including support staff) of the law firms of the undersigned counsel who are working directly on the joint defence effort or any ensuing litigation, in either case with respect to the Matter ("**Outside Counsel**"); and (ii) local external competition or regulatory counsel, economic consultants and other external advisers and external experts (including, in each

case, their support staff) working at the direction of the law firms on the Matter who shall undertake in writing to abide by this Agreement ("**Retained Experts**" and, together with Outside Counsel, the "**External Antitrust Clean Team**"). A list of key individuals who may receive Restricted Information shall be maintained by each firm of Retained Experts and there shall be a nominated individual at each firm of Retained Experts primarily responsible for ensuring compliance with this Agreement (the "**Responsible Person**").

- 1.3 **Restricted Information shall only be disclosed to the External Antitrust Clean Team and shall not be disclosed to any other person, entity, or agent, including officers or employees of the other Client (and specifically including inside counsel of the other Client and the corporate (or other) deal teams at the firm(s) of the undersigned counsel for the other Party), unless previously authorised in writing by the Party providing the Defence Materials (in which case the information ceases to be Restricted Information and becomes subject to Rule 21.3 of the City Code on Takeovers and Mergers).**
- 1.4 All Defence Materials that a Client intends to be provided as Restricted Information shall be clearly identified, and marked to the extent reasonably practicable, as "Outside Counsel/Retained Experts Only" (or equivalent). A Client shall mark electronic documents as "Outside Counsel/Retained Experts Only" by stating in the cover email that the attached Defence Materials are being provided on a "Outside Counsel/Retained Experts Only" (or equivalent) basis or, in any electronic data room, by adding "Outside Counsel/Retained Experts Only" to the names of the folders to which such Materials are uploaded.
- 1.5 For informational purposes only, examples of what may be provided as Restricted Information are set out in Annex 1. Any Restricted Information shall be dealt with by the External Antitrust Clean Team in the manner set out in Annex 1.
- 1.6 Restricted Information shall not include information which:
  - (a) has been expressly agreed in writing as not constituting Restricted Information by the Client that disclosed the information;
  - (b) is already in the public domain at the time of its supply;
  - (c) subsequently enters the public domain other than through a breach of the NDA, Clean Team Protocol (if entered to) or this Agreement; or
  - (d) is already in the lawful possession of the other Client (as can be demonstrated by written records).
- 1.7 It is expressly understood that nothing contained in this Agreement shall limit the right of the Clients to disclose any of their own documents or information, or any documents or information obtained independently and not pursuant to this Agreement, to anyone as they see fit.

- 1.8 For the avoidance of doubt, the Clients may, at any time, communicate in writing to each other that certain Restricted Information need no longer be held only by the External Antitrust Clean Team. At this point, the relevant information is no longer Restricted Information and can be shared with individuals outside the External Antitrust Clean Team (including, but not limited to, members of a Client's internal legal team) on such terms as may be agreed between the Clients and provided that such individuals have been approved in advance by the Clients and provided that the terms of the NDA, Clean Team Protocol (if entered into) and any other agreement in place between the Clients regarding the disclosure of confidential information between them in connection with the Transaction are observed.
- 1.9 The Clients, by each signing this Agreement, expressly consent and agree (and forthwith upon appointment of any Retained Expert in the future will expressly consent and agree) that Restricted Information of the other Client exchanged pursuant to this Agreement shall not be communicated to them, notwithstanding, among other provisions, the applicable rules of legal professional conduct or any similar provisions under other national, pan-national, state or local laws. The Clients shall not request that Restricted Information of the other Client be communicated to them.
- 1.10 The Clients and their undersigned counsel and any Retained Experts shall take all necessary steps to protect the confidentiality and/or applicable privilege of Defence Materials received from the other Client or undersigned counsel, including advising all persons permitted access to the information or Defence Materials of the contents of this Agreement and that the Defence Materials are privileged and subject to the terms of this Agreement.
- 1.11 No Client or undersigned counsel shall assert any claim of title or ownership over any Defence Materials received from the other Client or undersigned counsel, or any portion thereof. If any Defence Materials consist of computer software disclosed in object code form, no Client or undersigned counsel shall reverse engineer, reverse compile, or disassemble such object code, take any other steps to derive a source code equivalent thereof, or allow any other person to do so.
- 1.12 If any person or entity requests or demands, by subpoena or otherwise, any Defence Materials from any Client or undersigned counsel, that Client or undersigned counsel will immediately (unless prohibited by law) notify all counsel who are parties to this Agreement whose Client or who themselves may have rights in said materials and will take all steps necessary to permit the assertion of all applicable rights, privileges and immunities with respect to such Defence Materials, including permitting the other affected parties a reasonable opportunity to intervene and be heard, and otherwise cooperate fully with the other affected parties in any judicial proceedings relating to the disclosure of Defence Materials.
- 1.13 Nothing contained herein shall be deemed to create an attorney-client relationship between any undersigned counsel and anyone other than the Client of that counsel and the fact that undersigned counsel has entered this Agreement shall not in any way preclude that counsel

from representing any interest that may be construed to be adverse to any other party to this Agreement or be used as a basis for seeking to disqualify any undersigned counsel from representing any other party in this or any other proceeding, whether under a grant of immunity or otherwise, because of such counsel's participation in this Agreement; it is herein represented that each undersigned counsel to this Agreement has specifically advised his or her respective Client of this clause.

- 1.14 Nothing contained in this Agreement shall limit the rights of any Client or undersigned counsel (a) to independently develop, procure, use and/or market products or services similar to any disclosed in Defence Materials; or (b) to use ideas, concepts, or techniques which were previously used, developed, or known by it, provided that such activity does not violate the express terms of this Agreement or any other legal right of the other Client or undersigned counsel.
- 1.15 Nothing in this Agreement shall oblige any Client or undersigned counsel to share or communicate any information or Defence Materials or independently obtained or created materials with any other Client or undersigned counsel hereto.
- 1.16 Except as expressly set forth herein, no other past or future action of the Clients, course of conduct of any of the Clients, or failure to act by any of the Clients, including, without limitation, the execution or acceptance of this Agreement and the delivery and acceptance by the Clients of the Defence Materials has given rise to, will give rise to, has served as a basis for, or will serve as a basis for, any obligation or liability on the part of any of the Clients.
- 1.17 Any Client or undersigned counsel disclosing Defence Materials pursuant to this Agreement represents that it has the right to make such disclosure under this Agreement, but otherwise makes no representations or warranties, express or implied, as to the quality, accuracy, and completeness of any Defence Materials disclosed hereunder, and such Client or undersigned counsel, its affiliates and representatives shall have no liability whatsoever with respect to the use of or reliance upon the disclosed Defence Materials.
- 1.18 In the event that either Client chooses to withdraw from this Agreement, the appropriate counsel or Client shall promptly give notice of that fact to all other parties to this Agreement, and this Agreement shall terminate, except that (i) subject to clause 1.23, each Client and its undersigned counsel shall promptly (at its election) return or destroy (and confirm such destruction in writing) all Defence Materials it received from the other Client; and (ii) each Client and its undersigned counsel shall continue to be bound by the obligations of confidentiality provided herein with respect to Defence Materials previously furnished pursuant to this Agreement for a period of 2 years.
- 1.19 Triton, Triton's outside counsel and any Retained Experts instructed on behalf of Triton or its outside counsel shall provide to the UK Panel on Takeovers and Mergers (the "**Takeover Panel**") a written confirmation substantially in the forms set out in Appendix 1, Parts A -

D, or in such other form as the Takeover Panel requires. Triton and their undersigned counsel agree and acknowledge that the relevant confirmations being given by them and to be given by any Retained Expert engaged by Triton are being given by them for the benefit of Clinigen and may be relied upon and enforced by Clinigen as if expressly set out in Clinigen's favour in this Agreement. Triton shall take all necessary steps to ensure that it and its External Antitrust Clean Team comply with the arrangements set out in Annex 1 and Appendix 1 in respect of the Restricted Information.

- 1.20 Each undersigned counsel (and, to the extent applicable taking into account the limitations in clauses 1.2 and 1.3 above, Client) shall:
- (a) maintain a record of Defence Materials received, any copies made thereof and materials derived therefrom and the names of such persons to whom such information has been disclosed;
  - (b) keep Defence Materials and any copies thereof secure and in such a way as to prevent unauthorised access by any third party; and
  - (c) to the extent that Defence Materials are provided in electronic format, to the extent possible, not store such information on any computer, word processor or other device, unless access to the file is protected by password and restricted to those individuals who are actively engaged on the Matter and bound by this Agreement.
- 1.21 Each undersigned counsel (and, to the extent applicable taking into account the limitations in clauses 1.2 and 1.3 above, Client) shall:
- (a) limit access to Defence Materials to specific individuals who are directly involved in the Matter;
  - (b) inform the other immediately if it becomes aware that any Defence Materials have been disclosed to any person otherwise than in accordance with this Agreement.
- 1.22 Clients or undersigned counsel will procure that the Retained Experts will adhere to the obligations provided for in clauses 1.20, 1.21, and 1.23 and set out in any confirmations provided to the Takeover Panel.
- 1.23 Within 30 days after termination of the Transaction, or termination of discussions or negotiations on the Transaction, each Client, undersigned counsel and Retained Expert shall (at its election) return or destroy (and confirm such destruction in writing) all Defence Materials furnished by the other Client, undersigned counsel or Retained Expert pursuant to this Agreement, except to the extent otherwise required by law or by any applicable regulatory requirements or so as to comply with a bona fide internal document retention policy or other internal compliance or audit requirements.
- 1.24 This Agreement, its terms, and the activities conducted pursuant to this Agreement, constitute confidential Defence Materials. Each Client and undersigned counsel agrees not

to disclose this Agreement or its terms to anyone except insofar as permitted under the terms of this Agreement, provided that a copy of this Agreement may be provided to the Takeover Panel upon request and uploaded to the Clients' offer specific websites as required under the Takeover Code.

- 1.25 This Agreement shall be binding upon each Client's respective successors, legal representatives and permitted assigns. This Agreement is solely for the benefit of the Clients hereto.
- 1.26 This Agreement shall be governed exclusively by the laws of England and Wales and the Clients and undersigned counsel submit to the exclusive jurisdiction of the English courts.
- 1.27 This Agreement constitutes the entire and complete agreement between the Clients and undersigned counsel and supersedes any earlier joint defence agreements between or among any of the undersigned regarding the Transaction, whether written or oral, pursuant to which Defence Materials have been exchanged. Notwithstanding the foregoing, the NDA is excluded from this provision and remain in force.
- 1.28 Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable law. If any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibitions or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.
- 1.29 Each Client and undersigned counsel shall, and each Client shall procure that any Retained Experts or other External Antitrust Clean Team member retained by it shall, promptly notify the other Client upon becoming aware of any breach of this Agreement or any of the confirmations provided to the Takeover Panel in accordance with clause 1.19 above.
- 1.30 The Client and undersigned counsel acknowledge and agree that a breach of this Agreement by any Client, undersigned counsel, member of the External Antitrust Clean Team or Retained Expert may cause continuing and irreparable injury to the business of a Client as a direct result of such violation, for which remedies at law may be inadequate, and that any Client shall therefore be entitled, in the event of any actual or threatened violation of this Agreement or such confirmations by another Client or anyone retained by such Client, and in addition to any other remedies available to it, to seek a temporary restraining order and to seek injunctive relief against the other Client to prevent any violations of this Agreement, and to seek any other appropriate equitable relief.
- 1.31 No failure or delay by any Client or undersigned counsel to this Agreement to exercise any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.

- 1.32 This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one and the same instrument.
- 1.33 This Agreement may not be amended or modified except by a written agreement signed by each Client and undersigned counsel hereto, provided that any Client may unilaterally designate additional counsel representing such Client with respect to the Transaction or the Matter, who shall, upon executing a copy of this Agreement and delivering such executed copy to the other Client or its undersigned counsel, become parties to the Agreement in all respects as if they were original undersigned counsel.

**IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.**



**TRITON INVESTMENT MANAGEMENT LIMITED**



By:



Date:



**WHITE & CASE LLP**

Counsel to Triton Investment Management Limited

[Redacted]

By:

[Redacted]

Date:

[Redacted]

**CLINIGEN GROUP PLC**

[Redacted]

By:

[Redacted]

Date:

[Redacted]

**ASHURST LLP**

Counsel to Clinigen Group plc



By: 

Date: 

## **ANNEX 1**

### **EXAMPLES OF RESTRICTED INFORMATION**

- 1.1 Restricted Information may include (but is not limited to) competitively sensitive information such as:
- (a) turnover and asset data by geographic location;
  - (b) market share estimates and competitor/market analyses;
  - (c) recent, current or future prices or pricing terms (or terms related to pricing);
  - (d) recent, current, or future profit margins or profitability targets on specific products or projects;
  - (e) detailed costs;
  - (f) current or future strategies or policies relating to competition;
  - (g) forward-looking competitive information concerning future operation or strategies including market studies, business plans (including but not limited to sales/promotional plans, strategic plans, capital investment plans, expansion plans, plant closures, budgets, new product plans, or any other materials concerning future operations or strategies);
  - (h) the identity of current and potential customers or suppliers;
  - (i) the details of negotiations with present or potential suppliers;
  - (j) the details of ongoing or future tender participations;
  - (k) intentions to bid or not bid for specific contracts or tenders; and
  - (l) details of proprietary technologies or new product developments of a confidential nature.
- 1.2 As the due diligence process continues, the Clients reserve the right to expand this list as necessary.
- 1.3 Restricted Information will not be received by or made available to Triton, provided, however, that members of the External Antitrust Clean Team may share the conclusions that they reach based on the Restricted Information for

the purposes of providing Triton, with advice on any antitrust or regulatory risks associated with the Transaction, provided that such conclusions will not disclose the Restricted Information or any other information that enables the recipient to deduce the Restricted Information. Pursuant to paragraph 4.1(b) of Practice Statement 30 issued by the Takeover Panel, White & Case LLP confirms that [REDACTED] has been appointed as the individual who will review all advice to be provided by any member of the External Antitrust Clean Team to Triton to ensure that it does not disclose any Restricted Information or any other information which enables Triton to deduce the Restricted Information.

- 1.4 To the extent that any merger notifications, filings and submissions themselves include Restricted Information and (whether in draft or as submitted) are shared with Triton, Restricted Information will be redacted before these documents are shared with Triton.
- 1.5 To the extent that Triton or any of its other advisers (not being members of the External Antitrust Clean Team) are to participate in meetings or calls with any relevant antitrust or regulatory authorities or are to receive correspondence from any such authorities, then appropriate arrangements will be put in place to ensure that no Restricted Information is provided or accessible to or received by Triton or such other advisers.
- 1.6 Restricted Information will be provided separately from any other data and information being provided in connection with the Transaction (e.g. non-confidential business information needed for antitrust analysis, any other information exchanged by the parties for the purposes of due diligence or other analysis required in connection with the Transaction).
- 1.7 Restricted Information will clearly be identified as "Outside Counsel / Retained Experts Only" (or equivalent).
- 1.8 Restricted Information will be properly ring-fenced by the receiving external advisers (including from the corporate and transactional legal deal teams).
- 1.9 To the extent that Restricted Information is provided by email, or documents or materials containing or derived from the information are circulated by email, all such emails or documents will be filed either (i) to a separate ring-fenced filing system to which there is restricted access or (ii) in a filing system in which such information shall be password protected and the password(s) only given to members of the External Antitrust Clean Team.

- 1.10 To the extent that Restricted Information is provided via a dedicated online data room (the VDR), only the members of the External Antitrust Clean Team will have access to the VDR (or, as appropriate, the relevant section thereof).
- 1.11 If any firm advises that it cannot put these ring-fencing safeguards in place (e.g. due to IT limitations), then no Restricted Information will be provided to these firms and they will not be provided access to the VDR until an alternative structure has been agreed with the Takeover Panel and put in place.
- 1.12 The Takeover Panel will be promptly notified in the event that any Restricted Information does come into the possession of Triton or any of its advisers who do not form part of the External Antitrust Clean Team.

## **APPENDIX 1**

### **PART A**

#### **Form of Confirmation of Triton**

*[Letterhead of Triton]*

#### **Private and Confidential**

*[Addressee]*

The Takeover Panel  
One Angel Court,  
London, EC2R 7HJ

#### **By Email**

*[Date]*

Dear *[Addressee]*,

#### **TRITON INVESTMENT MANAGEMENT LIMITED ("TRITON") / CLINIGEN GROUP PLC ("CLINIGEN")**

- 1.1 We refer to the discussions you have had with White & Case LLP regarding competition/regulatory clearances with reference to a possible transaction involving Triton (in its capacity indirectly or directly as manager of funds known together as Triton V) and Clinigen (the "**Transaction**").
- 1.2 Pursuant to paragraph 4.1(c) of Practice Statement No 30, issued by the Takeover Panel and dated 8 October 2015 (and amended on 12 September 2016), we confirm that:
  - (a) we waive any rights to request the Restricted Information relating to Clinigen from any member of the External Antitrust Clean Team and waive any legal or professional obligations of disclosure which any member of the External Antitrust Clean Team may owe to us in respect of such Restricted Information;
  - (b) no director or employee of Triton will receive or have access to any Restricted Information relating to Clinigen until the offer becomes unconditional in all respects, and



(c) we will promptly inform the Takeover Panel if any Restricted Information relating to Clinigen comes into our possession.

1.3 Capitalised terms not otherwise defined here have the meaning ascribed to them in the confidentiality and joint defence agreement between Triton and Clinigen dated [●] 2021.

Yours sincerely,

---

[●], **Triton Investment Management Limited**

## PART B

### Form of Confirmation of Lead External Antitrust Legal Counsel

*[Letterhead of White & Case LLP]*

#### Private and Confidential

*[Addressee]*

The Takeover Panel  
One Angel Court,  
London, EC2R 7HJ

#### By Email

*[Date]*

Dear *[Addressee]*,

#### TRITON INVESTMENT MANAGEMENT LIMITED ("TRITON") / CLINIGEN GROUP PLC ("CLINIGEN")

- 1.1 We are retained as external legal counsel by Triton (in its capacity indirectly or directly as manager of funds known together as Triton V) to advise on competition and/or regulatory clearances relating to a possible transaction involving Triton and Clinigen (the "Transaction").
- 1.2 Pursuant to paragraph 4.1(a) of Practice Statement No 30 issued by the Takeover Panel and dated 8 October 2015 (and amended on 12 September 2016) ("**PS 30**"), we attach in the Annex a list of the key individuals proposed to be included in the External Antitrust Clean Team, including their positions and roles on the Transaction.
- 1.3 Pursuant to paragraph 4.1(b) of PS 30, we confirm that we have appointed [REDACTED] as the individual who has taken responsibility for ensuring that the procedures and information barriers will be implemented and complied with by White & Case LLP and who will review all advice to be provided by any member of the External Antitrust Clean Team to Triton to ensure that it does not disclose any Restricted Information relating to Clinigen or any other information which enables Triton to deduce such Restricted Information.
- 1.4 Pursuant to paragraph 4.1(d) of PS 30, we confirm that:
  - (a) we will not disclose any Restricted Information, or other information which enables a person to deduce the Restricted Information, to the

offeror or any person outside the External Antitrust Clean Team other than the relevant regulatory authorities;

- (b) effective information barriers and procedures have been implemented in order to ensure that the Restricted Information relating to Clinigen may only be accessed by members of the External Antitrust Clean Team; and
- (c) we will promptly inform the Takeover Panel if we become aware that any Restricted Information has come into the possession of anyone other than the members of the External Antitrust Clean Team.

1.5 To the extent that it is determined to be necessary or appropriate to instruct law firms in other jurisdictions, we will provide the Takeover Panel with the names of any such additional firms to be instructed and will seek the Takeover Panel's permission to provide Restricted Information to them on the basis of PS30.

1.6 Capitalised terms not otherwise defined here have the meaning ascribed to them in the confidentiality and joint defence agreement between Triton and Clinigen dated [●] 2021.

Yours sincerely,

---

[●], **White & Case LLP**

## **ANNEX**

### **LIST OF KEY INDIVIDUALS**

#### **PROPOSED TO BE INCLUDED IN THE EXTERNAL ANTITRUST CLEAN TEAM**

<b>Name</b>	<b>Position</b>	<b>Role in the Transaction</b>
[REDACTED]	Partner – White & Case LLP	Outside counsel to Triton
[REDACTED]	Partner – White & Case LLP	Outside counsel to Triton
[REDACTED]	Associate – White & Case LLP	Outside counsel to Triton
[REDACTED]	Associate – White & Case LLP	Outside counsel to Triton
[REDACTED]	Associate – White & Case LLP	Outside counsel to Triton
[REDACTED]	Associate – White & Case LLP	Outside counsel to Triton
[REDACTED]	Trainee Solicitor – White & Case LLP	Outside counsel to Triton
[REDACTED]	Practice Assistant – White & Case LLP	Support to outside counsel to Triton

## PART C

### Form of Confirmation of Retained Expert Firm

*[Letterhead of consulting firm]*

#### Private and Confidential

*[Addressee]*

The Takeover Panel  
One Angel Court,  
London, EC2R 7HJ

#### By Email

*[Date]*

Dear *[Addressee]*,

#### TRITON INVESTMENT MANAGEMENT LIMITED ("TRITON") / CLINIGEN GROUP PLC ("CLINIGEN")

- 1.1 We are retained by Triton (in its capacity indirectly or directly as manager of funds known together as Triton V) to assist in the analysis and preparation of filings and submissions for competition and/or regulatory clearances in relation to a possible transaction involving Triton and Clinigen (the "**Transaction**").
- 1.2 Pursuant to paragraph 4.1(a) of Practice Statement No 30 issued by the Takeover Panel and dated 8 October 2015 (and amended on 12 September 2016) ("**PS 30**"), we attach in the Annex a list of the key individuals proposed to be included in the External Antitrust Clean Team, including their positions and roles on the Transaction.
- 1.3 Pursuant to paragraph 4.1(b) of PS 30, we confirm that we have appointed *[name of Responsible Person]* as the individual who has taken responsibility for ensuring that the procedures and information barriers will be implemented and complied with by *[name of consulting firm]*.
- 1.4 Pursuant to paragraph 4.1(d) of PS 30, we confirm that:
  - (a) we will not disclose any Restricted Information relating to Clinigen, or other information which enables a person to deduce such Restricted

Information, to the offeror or any person outside the External Antitrust Clean Team other than the relevant regulatory authorities;

- (b) effective information barriers and procedures have been implemented in order to ensure that the Restricted Information relating to Clinigen may only be accessed by members of the External Antitrust Clean Team; and
- (c) we will promptly inform the Takeover Panel if we become aware that any Restricted Information relating to Clinigen has come into the possession of anyone other than the members of the External Antitrust Clean Team.

1.5 Capitalised terms not otherwise defined here have the meaning ascribed to them in the confidentiality and joint defence agreement between Triton and Clinigen dated [●] 2021.

Yours sincerely,

*[Responsible Person must be signatory to this confirmation]*

## ANNEX

### LIST OF KEY INDIVIDUALS

#### PROPOSED TO BE INCLUDED IN THE EXTERNAL ANTITRUST CLEAN TEAM

Name	Position	Role in the Transaction
[●]	[●]	Consultant to Triton
[●]	[●]	Consultant to Triton
[●]	[●]	Consultant to Triton

## PART D

### Form of Confirmation of Retained Expert Firm

*[Letterhead of independent economic experts]*

#### Private and Confidential

*[Addressee]*

The Takeover Panel  
One Angel Court,  
London, EC2R 7HJ

#### By Email

*[Date]*

Dear *[Addressee]*,

#### TRITON INVESTMENT MANAGEMENT LIMITED ("TRITON") / CLINIGEN GROUP PLC ("CLINIGEN")

- 1.1 We are retained by Triton (in its capacity indirectly or directly as manager of funds known together as Triton V) to assist in the economic analysis and preparation of filings and submissions for competition and/or regulatory clearances in relation to a possible transaction involving Triton and Clinigen (the "**Transaction**").
- 1.2 Pursuant to paragraph 4.1(a) of Practice Statement No 30 issued by the Takeover Panel and dated 8 October 2015 (and amended on 12 September 2016) ("**PS 30**"), we attach in the Annex a list of the key individuals proposed to be included in the External Antitrust Clean Team, including their positions and roles on the Transaction.
- 1.3 Pursuant to paragraph 4.1(b) of PS 30, we confirm that we have appointed *[name of Responsible Person]* as the individual who has taken responsibility for ensuring that the procedures and information barriers will be implemented and complied with by *[name of consulting firm]*.
- 1.4 Pursuant to paragraph 4.1(d) of PS 30, we confirm that:
  - (a) we will not disclose any Restricted Information relating to Clinigen, or other information which enables a person to deduce such Restricted



Information, to the offeror or any person outside the External Antitrust Clean Team other than the relevant regulatory authorities;

- (b) effective information barriers and procedures have been implemented in order to ensure that the Restricted Information relating to Clinigen may only be accessed by members of the External Antitrust Clean Team; and
- (c) we will promptly inform the Takeover Panel if we become aware that any Restricted Information relating to Clinigen has come into the possession of anyone other than the members of the External Antitrust Clean Team.

1.5 Capitalised terms not otherwise defined here have the meaning ascribed to them in the confidentiality and joint defence agreement between Triton and Clinigen dated [●] 2021.

Yours sincerely,

*[Responsible Person must be signatory to this confirmation]*

## ANNEX

### LIST OF KEY INDIVIDUALS

#### PROPOSED TO BE INCLUDED IN THE EXTERNAL ANTITRUST CLEAN TEAM

Name	Position	Role in the Transaction
[●]	[●]	Consultant to Triton
[●]	[●]	Consultant to Triton
[●]	[●]	Consultant to Triton